Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Ta-Chiang Liu
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Procedures
Living Beings
Physiology
Disorders
Anatomy
Concepts & Ideas
Chemicals & Drugs
Sign-in to see full Profile
Network (preview)
6
Martuza, Robert
6
rabkin, samuel
4
Kirn, David
3
Kuroda, Toshihiko
3
Hallden, Gunnel
3
Brooks, Gabriel
3
Francis, Jennelle
3
Wang, Yaohe
3
Lemoine, Nicholas
2
Todo, Tomoki
2
Fukuhara, Hiroshi
2
Kurtz, Andreas
1
Kwon, Hyuk-Chan
1
Lee, Yu-Yun
1
Han, Sang Young
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Ta-Chiang Liu (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Chang Ju-Fang; Chen Pei-Jer; Sze Daniel Y; Reid Tony; Bartlett David; Kirn David H; Liu Ta-Chiang
Oncolytic virotherapy for advanced liver tumours.
Journal of cellular and molecular medicine 2009;13(7):1238-47.
-
2009: Huang Pin-I; Chang Ju-Fang; Kirn David H; Liu Ta-Chiang
Targeted genetic and viral therapy for advanced head and neck cancers.
Drug discovery today 2009;14(11-12):570-8.
-
2009: Wakimoto Hiroaki; Kesari Santosh; Farrell Christopher J; Curry William T; Zaupa Cecile; Aghi Manish; Kuroda Toshihiko; Stemmer-Rachamimov Anat; Shah Khalid; Liu Ta-Chiang; Jeyaretna Deva S; Debasitis Jason; Pruszak Jan; Martuza Robert L; Rabkin Samuel D
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
Cancer research 2009;69(8):3472-81.
-
2009: Aghi Manish K; Liu Ta-Chiang; Rabkin Samuel; Martuza Robert L
Hypoxia enhances the replication of oncolytic herpes simplex virus.
Molecular therapy : the journal of the American Society of Gene Therapy 2009;17(1):51-6.
-
2009: Liu Ta-Chiang; Chen I-Shu; Lin Tzu-Kai; Lee J Yu-Yun; Kirn David; Tsao Chao-Jung
Erythema elevatum diutinum as a paraneoplastic syndrome in a patient with pulmonary lymphoepithelioma-like carcinoma.
Lung cancer (Amsterdam, Netherlands) 2009;63(1):151-3.
-
2008: Liu Ta-Chiang; Hwang Tae-Ho; Bell John C; Kirn David H
Development of targeted oncolytic virotherapeutics through translational research.
Expert opinion on biological therapy 2008;8(9):1381-91.
-
2008: Liu Ta-Chiang; Hwang Taeho; Park Byeong-Ho; Bell John; Kirn David H
The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(9):1637-42.
-
2008: Liu Ta-Chiang; Hwang Tae-Ho; Bell John C; Kirn David H
Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(6):1006-8.
-
2008: Park Byeong-Ho; Hwang Taeho; Liu Ta-Chiang; Sze Daniel Y; Kim Jae-Seok; Kwon Hyuk-Chan; Oh Sung Yong; Han Sang-Young; Yoon Jin-Han; Hong Sook-Hee; Moon Anne; Speth Kelly; Park Chohee; Ahn Young-Joo; Daneshmand Manijeh; Rhee Byung Geon; Pinedo Herbert M; Bell John C; Kirn David H
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
The lancet oncology 2008;9(6):533-42.
-
2008: Liu Ta-Chiang; Castelo-Branco Pedro; Rabkin Samuel D; Martuza Robert L
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(6):1041-7.
-
2008: Liu Ta-Chiang; Thorne Stephen H; Kirn David H
Oncolytic adenoviruses for cancer gene therapy.
Methods in molecular biology (Clifton, N.J.) 2008;433():243-58.
-
2007: Liu Ta-Chiang; Kirn David
Targeting the untargetable: oncolytic virotherapy for the cancer stem cell.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(12):2060-1.
-
2007: Liu Ta-Chiang; Wakimoto Hiroaki; Martuza Robert L; Rabkin Samuel D
Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5897-902.
-
2007: Liu Ta-Chiang; Galanis Evanthia; Kirn David
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.
Nature clinical practice. Oncology 2007;4(2):101-17.
-
2007: Liu Ta-Chiang; Kirn David
Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.
Cancer research 2007;67(2):429-32.
-
2006: Liu Ta-Chiang; Zhang Tingguo; Fukuhara Hiroshi; Kuroda Toshihiko; Todo Tomoki; Martuza Robert L; Rabkin Samuel D; Kurtz Andreas
Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;14(6):789-97.
-
2006: Liu Ta-Chiang; Zhang Tingguo; Fukuhara Hiroshi; Kuroda Toshihiko; Todo Tomoki; Canron Xavier; Bikfalvi Andreas; Martuza Robert L; Kurtz Andreas; Rabkin Samuel D
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(22):6791-9.
-
2005: Liu Ta-Chiang; Kirn David
Viruses with deletions in antiapoptotic genes as potential oncolytic agents.
Oncogene 2005;24(40):6069-79.
-
2005: Liu T-C; Wang Y; Hallden G; Brooks G; Francis J; Lemoine N R; Kirn D
Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Gene therapy 2005;12(17):1333-46.
-
2004: Liu Ta-Chiang; Hallden Gunnel; Wang Yaohe; Brooks Gabriel; Francis Jennelle; Lemoine Nick; Kirn David
An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;9(6):786-803.
-
2003: Wang Yaohe; Hallden Gunnel; Hill Richard; Anand Arthi; Liu Ta-Chiang; Francis Jennelle; Brooks Gabriel; Lemoine Nick; Kirn David
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.
Nature biotechnology 2003;21(11):1328-35.
Sign-in to see more
